Khalsa Jag H, Bunt Gregory, Blum Kenneth, Maggirwar Sanjay B, Galanter Marc, Potenza Marc N
Division of Therapeutics and Medical Consequences, Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse, NIH, Special Volunteer, 16071 Industrial Drive, Gaithersburg, MD 20877 USA.
Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University School of Medicine, Ross Hall Room 502A, 2300 I Street, Washington, NWDC 20037 USA.
Curr Addict Rep. 2022;9(4):630-646. doi: 10.1007/s40429-022-00438-3. Epub 2022 Sep 7.
There have been many debates, discussions, and published writings about the therapeutic value of cannabis plant and the hundreds of cannabinoids it contains. Many states and countries have attempted, are attempting, or have already passed bills to allow legal use of cannabinoids, especially cannabidiol (CBD), as medicines to treat a wide range of clinical conditions without having been approved by a regulatory body. Therefore, by using PubMed and Google Scholar databases, we have reviewed published papers during the past 30 years on cannabinoids as medicines and comment on whether there is sufficient clinical evidence from well-designed clinical studies and trials to support the use of CBD or any other cannabinoids as medicines.
Current research shows that CBD and other cannabinoids currently are not ready for formal indications as medicines to treat a wide range of clinical conditions as promoted except for several exceptions including limited use of CBD for treating two rare forms of epilepsy in young children and CBD in combination with THC for treating multiple-sclerosis-associated spasticity.
Research indicates that CBD and several other cannabinoids have to treat multiple clinical conditions, but more preclinical, and clinical studies and clinical trials, which follow regulatory guidelines, are needed to formally recommend CBD and other cannabinoids as medicines.
关于大麻植物及其所含数百种大麻素的治疗价值，存在诸多争论、讨论及已发表的著作。许多州和国家已尝试、正在尝试或已经通过法案，允许合法使用大麻素，尤其是大麻二酚（CBD），作为治疗多种临床病症的药物，而这些药物尚未获得监管机构的批准。因此，通过使用PubMed和谷歌学术数据库，我们回顾了过去30年中关于大麻素作为药物的已发表论文，并就精心设计的临床研究和试验是否有足够的临床证据支持将CBD或任何其他大麻素用作药物发表评论。
目前的研究表明，除了少数例外情况，包括有限地使用CBD治疗幼儿的两种罕见癫痫形式以及CBD与四氢大麻酚联合治疗多发性硬化相关痉挛外，CBD和其他大麻素目前还未准备好作为治疗多种临床病症的药物获得正式适应证。
研究表明，CBD和其他几种大麻素具有治疗多种临床病症的潜力，但需要更多遵循监管指南的临床前和临床研究及临床试验，才能正式推荐将CBD和其他大麻素用作药物。
